{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.9","upperLimit":"71.4","value":"59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"NUMBER","populationDescription":"Intention to treat","reportingStatus":"POSTED","timeFrame":"up to 12 months","title":"Complete Remission Rate by Independent Review Group","type":"SECONDARY","unitOfMeasure":"percent of participants"}